ISRCTN97767916 https://doi.org/10.1186/ISRCTN97767916

# Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

| | | |
|---|---|---|
| **Submission date**<br>01/07/2001 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol |
| **Registration date**<br>01/07/2001 | **Overall study status**<br>Completed | [_] Statistical analysis plan<br>[_] Results |
| **Last Edited**<br>26/02/2015 | **Condition category**<br>Cancer | [_] Individual participant data<br>[_] Record updated in last year |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
- - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

BNLI2

# Study information

### Scientific Title
Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

### Study objectives
Evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Secondary study design
Randomised controlled trial

### Study setting(s)
Hospital

### Study type(s)
Treatment

### Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied
Hodgkin's lymphoma

### Interventions
1. Regimen A: Chemotherapy, chlorambucil vincristine, procarbazine and prednisolone (LOPP) alternating every 28 days with etoposide, vinblastine, adriamycin and prednisolone (EVAP). A course of chemotherapy is given every 28 days for a minimum of six cycles.
2. Regimen B: Chemotherapy, chlorambucil, vincristine, procarbazine and prednisolone, etoposide, vinblastine, adriamycin (LOPP/EVA) repeated every 28 days for a minimum of six cycles.

### Intervention Type
Other

### Phase
Not Specified

### Primary outcome measure
Not provided at time of registration

### Secondary outcome measures
Not provided at time of registration

### Overall study start date
01/01/1999

### Completion date
31/12/2005

## Eligibility

### Key inclusion criteria
1. Aged over 15 years
2. Stage IB, IIB, III or IV Hodgkin's Disease.
3. Histologically confirmed Hodgkin's lymphoma
4. Free from any potentially life threatening disease other than Hodgkin's Disease
5. Lymphangiography or Computed Tomography (CT) scan of the abdomen
6. No previous treatment except as an emergency measure

### Participant type(s)
Patient

### Age group
Adult

### Sex
Both

### Target number of participants
Not provided at time of registration

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/01/1999

### Date of final enrolment
31/12/2005

## Locations

### Countries of recruitment

England

United Kingdom

**Study participating centre**
**MRC Clinical Trials Unit**
London
United Kingdom
NW1 2DA

# Sponsor information

**Organisation**
Cancer Research UK (CRUK) (UK)

**Sponsor details**
PO Box 123
Lincoln's Inn Fields
London
United Kingdom
WC2A 3PX
+44 (0)207 317 5186
kate.law@cancer.org.uk

**Sponsor type**
Charity

**Website**
http://www.cancer.org.uk

**ROR**
https://ror.org/054225q67

# Funder(s)

**Funder type**
Charity

**Funder Name**
Lymphoma Research Trust

**Funder Name**
Cancer Research UK

**Alternative Name(s)**
CR_UK, Cancer Research UK - London, CRUK

**Funding Body Type**
Private sector organisation

**Funding Body Subtype**
Other non-profit organizations

**Location**
United Kingdom

**Funder Name**
Lisa Lear Fund

**Funder Name**
Isle of Man Anti-Cancer Association

## Results and Publications

**Publication and dissemination plan**
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration